You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 229 Discovery of ganglioside GM2 activator as a novel proteomic biomarker associated with response to treatment in first-line melanoma subjects treated with PD-1 immunotherapy

Article Text

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Checkpoint blockade therapy
229 Discovery of ganglioside GM2 activator as a novel proteomic biomarker associated with response to treatment in first-line melanoma subjects treated with PD-1 immunotherapy

https://doi.org/10.1136/jitc-2020-SITC2020.0229

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.